Liver Cancer Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- You have been diagnosed with a specific type of liver cancer (called infiltrative hepatocellular carcinoma, or HCC) confirmed by MRI or CT scan
- Your liver is functioning reasonably well, rated as Child-Pugh class A or B (confirm with trial site), and you are generally able to carry out daily activities with little or no limitation
- Your first treatment for this condition is a drug called Lenvatinib
- Depending on which group you are assigned to, you would receive either Lenvatinib alone, or a combination of Lenvatinib, a procedure called HAIC (a way of delivering chemotherapy directly to the liver), and an immunotherapy drug called a PD-1 inhibitor
- You have no history of any other type of cancer
- The cancer has not spread into the heart or the large vein connected to the heart (vena cava)
Who may not be able to join:
- Your liver cancer has a defined outer layer or capsule surrounding the tumour
- You are under 18 years old or over 75 years old
- Your first treatment was a procedure called TACE (a different type of liver-directed therapy)
- You previously received a drug called sorafenib or other systemic treatments, with or without an immunotherapy drug, after HAIC
- Your medical imaging records are incomplete
- You were lost to follow-up within the first three months after starting treatment
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Feng Duan, MD, Chinese PLA General Hospital
Phone: 86 19868000115
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Overall survival
Can't join this trial?
Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.